Protac-mediated degradation of the TFE3-ASPSCR1 fusion: targeted therapy for alveolar soft part sarcoma
Active Project Grant Awarded Last action
- Award ID
- HT9425261E449
- Recipient
-
Brigham & Womens Hospital Inc. UEI QN6MS4VN7BD1 Part of Partners Healthcare System Incorporated
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $140,000
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 0% complete
- Place of performance
- Boston, MA 02115, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded Brigham & Women's Hospital Inc. $140,000 on November 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support protease-targeted chimera-mediated degradation of the TFE3-ASPSCR1 fusion protein as targeted therapy for alveolar soft part sarcoma. Performance occurs in Boston, Massachusetts through October 31, 2028. Brigham & Women's Hospital, operating as the Department of Faulkner Pathology and a subsidiary of Partners Healthcare System Incorporated, serves as the recipient. The program supports basic, applied, and advanced biomedical research to transform health care for Service Members and the American public through innovative research and investigation of medical solutions for battlefield and clinical use.
Quick answers
Who received award HT9425261E449?
HT9425261E449 was awarded to Brigham & Womens Hospital Inc. by Defense Health Agency (Department of Defense) on November 1, 2026.
How much is award HT9425261E449 worth?
$140,000 has been obligated on HT9425261E449.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award